Tilray Q4 revenue rises 25% on the back of international medical cannabis

Overview

• Canada-U.S. cannabis and beverage firm's fiscal Q4 revenue rose 25% yr/yr

• Adjusted EPS for fiscal Q4 rose to $0.05 from $0.01 a year ago

• Company posted a net loss in Q4, mainly due to non-cash charges

Outlook

• Tilray expects fiscal 2027 adjusted EBITDA of $68 mln to $75 mln

• Company anticipates annual revenue above $1 bln in fiscal 2027

• Tilray says regulatory uncertainty persists in U.S. cannabis market

Result Drivers

• INTERNATIONAL MEDICAL CANNABIS - Co said international medical cannabis revenue rose 34% for the year, driven by its European platform and pharmaceutical distribution network

• BEVERAGE SEGMENT EXPANSION - BrewDog acquisition and expanded partnerships drove beverage revenue and gross profit higher in Q4, with management citing improved performance and stabilization

• DISTRIBUTION GROWTH - Distribution net revenue and gross profit rose in Q4, reflecting expanded infrastructure and operating leverage

Company press release: ID:nGNXSqzsX

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• Wall Street's median 12-month price target for Tilray Brands Inc is C$7.25, about 26.7% above its July 27 closing price of C$5.72

Reuters Recommended Reads

• July 28 - Coca-Cola hails World Cup hydration breaks as it lifts annual forecasts

• July 26 - Brown-Forman board says unsolicited Sazerac takeover proposal not actionable

• July 28 - GSK Q2 sales beat analyst estimates on specialty medicines growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)